Molecular subtyping of small-cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies
Related Experiment Video
Updated: Aug 27, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Haiyong Wang1, Shuangxiu Wu2, Zhenzhen Li3
1Department of Internal Medicine-Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Abstract:
Small-cell lung cancer (SCLC) is an exceptionally lethal malignancy characterized by extremely high alteration rates and tumor heterogeneity, which limits therapeutic options. In contrast to non-small-cell lung cancer that develops rapidly with precision oncology, SCLC still remains outside the realm of precision medicine. No recurrent and actionable mutations have been detected. Additionally, a paucity of substantive tumor specimens has made it even more difficult to classify SCLC subtypes based on genetic background. We therefore carried out whole-exome sequencing (WES) on the largest available Chinese SCLC cohort. For the first time, we partitioned SCLC patients into three clusters with different genomic alteration profiles and clinical features based on their mutational signatures. We showed that these clusters presented differences in intratumor heterogeneity and genome instability. Moreover, a wide existence of mutually exclusive gene alterations, typically within similar biological functions, was detected and suggested a high SCLC intertumoral heterogeneity. Particularly, Cluster 1 presented the greatest potential to benefit from immunotherapy, and Cluster 3 constituted recalcitrant SCLC, warranting biomarker-directed drug development and targeted therapies in clinical trials. Our study would provide an in-depth insight into the genome characteristics of the Chinese SCLC cohort, defining distinct molecular subtypes as well as subtype-specific therapies and biomarkers. We propose tailoring differentiated therapies for distinct molecular subgroups, centering on a personalized precision chemotherapy strategy combined with immunization or targeted therapy for patients with SCLC.
Insights
This study identifies three distinct molecular subtypes of small-cell lung cancer (SCLC) in a Chinese cohort using whole-exome sequencing. These subtypes show varied genomic profiles and potential for tailored immunotherapies and targeted treatments.
Area of Science:
- Oncology
- Genomics
- Cancer Research
Background:
- Small-cell lung cancer (SCLC) is highly lethal with limited therapeutic options due to rapid progression and tumor heterogeneity.
- SCLC lacks actionable mutations, hindering precision medicine approaches unlike non-small-cell lung cancer.
- Classifying SCLC subtypes is challenging due to a scarcity of tumor specimens and genetic data.
Purpose of the Study:
- To perform whole-exome sequencing on the largest Chinese SCLC cohort to date.
- To identify distinct molecular subtypes within SCLC based on genomic alteration profiles and mutational signatures.
- To provide insights into SCLC genome characteristics for developing subtype-specific therapies and biomarkers.
Main Methods:
- Whole-exome sequencing (WES) was conducted on a large cohort of Chinese SCLC patients.
- Bioinformatic analysis was used to partition patients into clusters based on mutational signatures.
- Intratumor heterogeneity and genome instability were assessed across identified clusters.
Main Results:
- SCLC patients were successfully partitioned into three distinct clusters with unique genomic alteration profiles and clinical features.
- Significant differences in intratumor heterogeneity and genome instability were observed among the clusters.
- Mutually exclusive gene alterations within similar biological functions indicated high intertumoral heterogeneity in SCLC.
- Cluster 1 showed high potential for immunotherapy benefit, while Cluster 3 represented recalcitrant SCLC.
Conclusions:
- The study defines distinct molecular subtypes of SCLC in the Chinese population, offering an in-depth genomic insight.
- Tailored therapies, including personalized precision chemotherapy combined with immunotherapy or targeted agents, are proposed for distinct SCLC molecular subgroups.
- Identifying these subtypes is crucial for advancing biomarker-directed drug development and targeted therapies in clinical trials for SCLC.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...